Biotech’s bull market, Vertex’s gene therapy expansion, and more news from The Readout
SEBASTIEN BOZON/AFP via Getty Images
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! As ever, lots going on in the light-speed world of biotech. The sector’s rally is gathering steam, the FDA’s AI flexibility is getting lost in translation, and Democrats lose a seasoned biopharma policymaker.
